Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in Am J Surg Retrieve available abstracts of 14 articles: HTML format

Single Articles

May 2025
1. GUNDER MA, Stephens KR, Donica W, McMasters KM, et al
   Predicting who may benefit from adjuvant immunotherapy in stage IIB melanoma.
   Am J Surg. 2025;247:116450.
   PubMed     Abstract available
   
   
   February 2025
2. MORRISON SL, Han G, Elenwa F, Leong SP, et al
   Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis.
   Am J Surg. 2025 Feb 8:116243. doi: 10.1016/j.amjsurg.2025.116243.
   PubMed     Abstract available
   
   
   January 2025
3. WILSON NR, Angeles CV, Haykal T
   Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer?
   Am J Surg. 2025 Jan 21:116207. doi: 10.1016/j.amjsurg.2025.116207.
   PubMed    
   
   
   December 2024
4. MCCAHILL LE
   Changes in the surgical management of melanoma and measures to implement change.
   Am J Surg. 2024;241:116129.
   PubMed     Abstract available
   
   
   October 2024
5. JIMINEZ V, Montgomery KB, Hollenquest B, Broman KK, et al
   Long-term outcomes of nodal surveillance practices in sentinel node positive melanoma: An early post MSLT-II cohort.
   Am J Surg. 2024;239:116049.
   PubMed     Abstract available
   
   
   August 2024
6. SHEN N, Ramanathan S, Horns JJ, Hyngstrom JR, et al
   The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018).
   Am J Surg. 2024;237:115896.
   PubMed     Abstract available
   
   
   June 2024
7. HAYKAL T, Contreras C
   Adjuvant PD-1-based therapies for high-risk resected melanomas are here to stay.
   Am J Surg. 2024 Jun 1:115791. doi: 10.1016/j.amjsurg.2024.115791.
   PubMed    
   
   
   February 2024
8. VALENZUELA CD, Fowler G, Kozuma K, Kusaka S, et al
   Long-term outcomes after amputation and sentinel node biopsy for subungual melanoma: A single-institution series.
   Am J Surg. 2024 Feb 24:S0002-9610(24)00138-7. doi: 10.1016/j.amjsurg.2024.
   PubMed     Abstract available
   
   
   
9. DOWNEY J, Hamm J, Baliski C
   Impact of extra-nodal extension and AJCC lymph node staging in predicting recurrence following lymphadenectomy in patients with melanoma.
   Am J Surg. 2024 Feb 2:S0002-9610(24)00029-1. doi: 10.1016/j.amjsurg.2024.
   PubMed     Abstract available
   
   
   October 2023
10. WILSON AK, Lourdault K, Ostad T, Stern S, et al
    Is therapeutic lymph node dissection of value for lymph node recurrence in melanoma?
    Am J Surg. 2023 Oct 17:S0002-9610(23)00564-0. doi: 10.1016/j.amjsurg.2023.
    PubMed     Abstract available
    
    
    September 2023
11. HANUSCHAK D, DePiero M, DeMoraes M, Bailly S, et al
    The impact of COVID-19 on patients diagnosed with melanoma, breast, and colorectal cancer.
    Am J Surg. 2023 Sep 29:S0002-9610(23)00496-8. doi: 10.1016/j.amjsurg.2023.
    PubMed     Abstract available
    
    
    
12. ISTL AC
    Skin in the Game: Surgical delays in our patients with melanoma.
    Am J Surg. 2023 Sep 15:S0002-9610(23)00473-7. doi: 10.1016/j.amjsurg.2023.
    PubMed    
    
    
    May 2023
13. SCHWANTES IR, Sutton T, Behrens S, Fowler G, et al
    Metastasectomy for metastatic melanoma in the era of effective systemic therapy.
    Am J Surg. 2023 May 23:S0002-9610(23)00184-8. doi: 10.1016/j.amjsurg.2023.
    PubMed     Abstract available
    
    
    April 2023
14. HEWITT DB, Beane JD, Grignol VP, Contreras CM, et al
    Association between surgical delay and outcomes among patients with invasive cutaneous melanoma.
    Am J Surg. 2023 Apr 29:S0002-9610(23)00183-6. doi: 10.1016/j.amjsurg.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.